Unknown

Dataset Information

0

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).


ABSTRACT: In patients with chronic myelogenous leukemia (CML), point mutations in the BCR-ABL1 kinase domain are the most common cause of treatment failure with a tyrosine kinase inhibitor (TKI). It is not clear whether the splice variant BCR-ABL1(35INS) is also associated with treatment failure.We reviewed all CML patients who had BCR-ABL1 kinase mutation analysis performed between August 1, 2007, and January 15, 2014. Patients who had BCR-ABL1(35INS) detected had their medical records reviewed to determine response to TKI therapy.Two hundred and eighty four patients had kinase mutation testing performed; of these, 64 patients (23%) had BCR-ABL1(35INS) detected. Forty-five patients were in chronic phase (70%), 10 were in accelerated phase (16%), 6 were in blastic phase (9%), and 3 were in other settings (5%). Of the 34 chronic phase patients who began therapy with imatinib, 23 patients (68%) failed therapy: 8 patients (24%) had primary refractory disease, 11 patients (32%) progressed, and 4 patients (12%) had disease progression after dose interruption. In contrast to the patients with disease progression or lack of response, none of 23 patients who were responding to imatinib had BCR-ABL1(35INS) detected. DNA sequencing of commonly mutated spliceosomal genes SF3B1, U2AF1, SRSF2, ZRSR2, SFA31, PRPF408, U2A565, and SF1 did not reveal mutations in seven BCR-ABL1(35INS) -positive patients tested.The splice variant BCR-ABL1(35INS) is frequently found in patients who are resistant to imatinib. Mutations in the commonly mutated spliceosomal proteins do not contribute to this association.

SUBMITTER: Berman E 

PROVIDER: S-EPMC5625826 | biostudies-other | 2016 Oct

REPOSITORIES: biostudies-other

altmetric image

Publications

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

Berman Ellin E   Jhanwar Suresh S   Hedvat Cyrus C   Arcila Maria E ME   Wahab Omar Abdel- OA   Levine Ross R   Maloy Molly M   Ma Wanlong W   Albitar Maher M  

Leukemia research 20160812


<h4>Purpose</h4>In patients with chronic myelogenous leukemia (CML), point mutations in the BCR-ABL1 kinase domain are the most common cause of treatment failure with a tyrosine kinase inhibitor (TKI). It is not clear whether the splice variant BCR-ABL1(35INS) is also associated with treatment failure.<h4>Patients and methods</h4>We reviewed all CML patients who had BCR-ABL1 kinase mutation analysis performed between August 1, 2007, and January 15, 2014. Patients who had BCR-ABL1(35INS) detected  ...[more]

Similar Datasets

| S-EPMC2254539 | biostudies-literature
| S-EPMC6334626 | biostudies-literature
| S-EPMC3041785 | biostudies-literature
| S-EPMC3156347 | biostudies-literature
| S-EPMC4581365 | biostudies-literature
| S-EPMC2577410 | biostudies-literature
| S-EPMC4559757 | biostudies-literature
| S-EPMC6651622 | biostudies-literature
| S-EPMC5223104 | biostudies-literature
| S-EPMC5620182 | biostudies-literature